Literature DB >> 25034653

Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients.

Mariana Ferreira Leal1, Danielle Queiroz Calcagno, Janete Chung, Vanessa Morais de Freitas, Samia Demachki, Paulo Pimentel Assumpção, Roger Chammas, Rommel Rodríguez Burbano, Marília Cardoso Smith.   

Abstract

Gastric cancer (GC) is the second highest cause of cancer mortality worldwide. However, nowadays, most of the studies aiming to understand the gastric carcinogenesis analyzed tumors of individuals from Asian population and, thus, may not reflect the distinct biological and clinical behaviors among GC processes. Since several membrane proteins have been implicated in carcinogenesis, we aimed to evaluate ANXA2 and GAL3 role in gastric tumors and GC cell lines of individuals from northern Brazil. The cellular localization of ANXA2 and GAL3 in the GC cell lines was evaluated by immunofluorescence. Gene expression was evaluated by real-time reverse-transcription PCR and protein expression by Western blot in gastric adenocarcinomas and non-neoplastic gastric samples, as well as in GC cell lines. ANXA2 and GAL3 were presented as dots in the plasma membrane and cytoplasm in ACP02 and ACP03 cell lines. ANXA2 mRNA expression was up-regulated in 32.14 % of gastric tumors compared to non-neoplastic tissues. ANXA2 up-regulation was associated with the metastasis process in vivo and with cell line invasive behavior. GAL3 protein expression was at least 1.5-fold reduced in 50 % of gastric tumors. The reduced GAL3 expression was associated with the presence of distant metastasis and with a higher invasive phenotype in vitro. Our study shows that ANXA2 and GAL3 deregulated expression was associated with an invasive phenotype in GC cell lines and may contribute to metastasis in GC patients. Therefore, these proteins may have potential prognostic relevance for GC of individuals from northern Brazil.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034653     DOI: 10.1007/s10238-014-0299-0

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  31 in total

1.  Gastric cancer--an enigmatic and heterogeneous disease.

Authors:  Manish A Shah; Jaffer A Ajani
Journal:  JAMA       Date:  2010-05-05       Impact factor: 56.272

2.  Decreased expression of galectin-3 is associated with progression of human breast cancer.

Authors:  V Castronovo; F A Van Den Brûle; P Jackers; N Clausse; F T Liu; C Gillet; M E Sobel
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

3.  The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers.

Authors:  G Choufani; N Nagy; S Saussez; H Marchant; P Bisschop; M Burchert; A Danguy; S Louryan; I Salmon; H J Gabius; R Kiss; S Hassid
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

4.  Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer.

Authors:  Paul J Adam; Robert Boyd; Kerry L Tyson; Graham C Fletcher; Alasdair Stamps; Lindsey Hudson; Helen R Poyser; Nick Redpath; Matthew Griffiths; Graham Steers; Adrian L Harris; Sonal Patel; Joanne Berry; Julie A Loader; R Reid Townsend; Laurent Daviet; Pierre Legrain; Raj Parekh; Jonathan A Terrett
Journal:  J Biol Chem       Date:  2002-12-10       Impact factor: 5.157

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Clinical implication of 14-3-3 epsilon expression in gastric cancer.

Authors:  Mariana Ferreira Leal; Danielle Queiroz Calcagno; Sâmia Demachki; Paulo Pimentel Assumpção; Roger Chammas; Rommel Rodríguez Burbano; Marília de Arruda Cardoso Smith
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

7.  Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma.

Authors:  K Emoto; H Sawada; Y Yamada; H Fujimoto; Y Takahama; M Ueno; T Takayama; H Uchida; K Kamada; A Naito; S Hirao; Y Nakajima
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

8.  Li-cadherin is inversely correlated with galectin-3 expression in gastric cancer.

Authors:  Wei-Guo Dong; Qiong-Fang Yu; Yu Xu; Li-Fang Fan
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

9.  Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas.

Authors:  F A van den Brûle; A Berchuck; R C Bast; F T Liu; C Gillet; M E Sobel; V Castronovo
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

10.  Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications.

Authors:  Mariana Ferreira Leal; Tatiane Katsue Furuya Mazzotti; Danielle Queiroz Calcagno; Priscila Daniele Ramos Cirilo; Margarita Cortes Martinez; Samia Demachki; Paulo Pimentel Assumpção; Roger Chammas; Rommel Rodríguez Burbano; Marília Cardoso Smith
Journal:  BMC Gastroenterol       Date:  2014-01-10       Impact factor: 3.067

View more
  12 in total

Review 1.  Dietary phytochemicals as the potential protectors against carcinogenesis and their role in cancer chemoprevention.

Authors:  Alena Liskova; Patrik Stefanicka; Marek Samec; Karel Smejkal; Pavol Zubor; Tibor Bielik; Kristina Biskupska-Bodova; Taeg Kyu Kwon; Jan Danko; Dietrich Büsselberg; Mariusz Adamek; Luis Rodrigo; Peter Kruzliak; Aleksandr Shleikin; Peter Kubatka
Journal:  Clin Exp Med       Date:  2020-02-03       Impact factor: 3.984

2.  Expression and significance of annexin A2 in patients with gastric adenocarcinoma and the association with E-cadherin.

Authors:  Yuehua Han; Jun Ye; Ying Dong; Zhipeng Xu; Qin DU
Journal:  Exp Ther Med       Date:  2015-06-10       Impact factor: 2.447

Review 3.  Potentially Curable Cancers of the Esophagus and Stomach.

Authors:  Elena Elimova; Dilsa Mizrak Kaya; Kazuto Harada; Jaffer A Ajani
Journal:  Mayo Clin Proc       Date:  2016-09       Impact factor: 7.616

Review 4.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

Review 5.  What gastric cancer proteomic studies show about gastric carcinogenesis?

Authors:  Mariana Ferreira Leal; Fernanda Wisnieski; Carolina de Oliveira Gigek; Leonardo Caires do Santos; Danielle Queiroz Calcagno; Rommel Rodriguez Burbano; Marilia Cardoso Smith
Journal:  Tumour Biol       Date:  2016-04-28

6.  Biological characteristics of a novel giant cell tumor cell line derived from spine.

Authors:  Zhenhua Zhou; Yan Li; Leqin Xu; Xudong Wang; Su Chen; Cheng Yang; Jianru Xiao
Journal:  Tumour Biol       Date:  2016-01-23

7.  Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients.

Authors:  Faruk Tas; Elif Bilgin; Didem Tastekin; Kayhan Erturk; Derya Duranyildiz
Journal:  J Gastrointest Cancer       Date:  2016-06

8.  Galectin-3 Inhibition Is Associated with Neuropathic Pain Attenuation after Peripheral Nerve Injury.

Authors:  Zhicong Ma; Qi Han; Xiaolei Wang; Zisheng Ai; Yongjun Zheng
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 9.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

10.  Serum galectin-3 as a potential marker for gastric cancer.

Authors:  Daye Cheng; Bin Liang; Yunhui Li
Journal:  Med Sci Monit       Date:  2015-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.